ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Enliven Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$38.70+1.38 (+3.70%)
Close on Oct 19, 2026
- Market cap
- $2.56B
- P/E (TTM)
- –
- Dividend yield
- –
Community
Notes and questions about Enliven Therapeutics from other investors
No posts about ELVN yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.